Itama Ranoraya PT
IDX:IRRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Amco India Ltd
BSE:530133
|
IN |
|
Guizhou Zhenhua E-chem Inc
SSE:688707
|
CN |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| ID |
I
|
Itama Ranoraya PT
IDX:IRRA
|
594.1B IDR |
Loading...
|
|
| US |
|
Mckesson Corp
NYSE:MCK
|
106.1B USD |
Loading...
|
|
| US |
|
Cencora Inc
NYSE:COR
|
62.2B USD |
Loading...
|
|
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
61.6B USD |
Loading...
|
|
| US |
|
Cardinal Health Inc
NYSE:CAH
|
50.7B USD |
Loading...
|
|
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
31.2B AUD |
Loading...
|
|
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.3B CNY |
Loading...
|
|
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
61.3B CNY |
Loading...
|
|
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.9B USD |
Loading...
|
|
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW |
Loading...
|
|
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
63.4B HKD |
Loading...
|
Market Distribution
| Min | -87 446.9% |
| 30th Percentile | 9.8% |
| Median | 20.5% |
| 70th Percentile | 37% |
| Max | 1 023 491.4% |
Other Profitability Ratios
Itama Ranoraya PT
Glance View
PT Itama Ranoraya Tbk operates as a medical devices distributor. The company is headquartered in Jakarta Timur, Dki Jakarta and currently employs 169 full-time employees. The company went IPO on 2019-10-15. The firm operates in the field of wholesale trading of laboratory equipment, pharmaceutical equipment, and medical devices for humans. The firm carries out its operations through four products, namely the non-electromedical sterile medical devices, in-vitro diagnostic, electromedical sterile medical devices, and other products. Its business segment focuses on in-vitro diagnostic (IVD), medical imaging, surgical instrument and disposable, critical care, blood banking and transfusion, cardiovascular, brain management, cancer, urology, and maternal and neonatal care. Its products include Oneject, Abbott, Terumo, Becton Dickinson (BD), HMD, Vestfrost, Balmed, iGene, AVIMAC, and HemoCue.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Itama Ranoraya PT is 19.6%, which is below its 3-year median of 21.2%.
Over the last 3 years, Itama Ranoraya PT’s Gross Margin has increased from 19.3% to 19.6%. During this period, it reached a low of 18.5% on Sep 30, 2024 and a high of 25.7% on Sep 30, 2023.
